Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Tongji Hospital
Tongji Hospital
Xijing Hospital
Fudan University
Fudan University
Changhai Hospital
Changhai Hospital
Infinity Pharmaceuticals, Inc.
Fujian Cancer Hospital
Shanghai Hengrui Pharmaceutical Co., Ltd.
Hunan Cancer Hospital
Tianjin Medical University Cancer Institute and Hospital
Ruijin Hospital
Ludwig-Maximilians - University of Munich
Fudan University
The First Affiliated Hospital with Nanjing Medical University
Zhongshan Hospital Xiamen University
Xijing Hospital
Fudan University
IRCCS San Raffaele
Institute of Molecular Medicine and Biomedical Research
ChineseAMS
Fudan University
Fudan University
Ruijin Hospital
Jiangsu HengRui Medicine Co., Ltd.
Australasian Gastro-Intestinal Trials Group
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Shengjing Hospital
The First Hospital of Jilin University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Sichuan Cancer Hospital and Research Institute
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Guangdong Association of Clinical Trials
Huazhong University of Science and Technology
Chinese PLA General Hospital
Tianjin Medical University Cancer Institute and Hospital
Tang-Du Hospital
The First Affiliated Hospital of Xiamen University
Nagoya University
Fudan University
Qilu Pharmaceutical Co., Ltd.
Peking University Third Hospital
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Guangdong Association of Clinical Trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ChineseAMS
Chinese PLA General Hospital